Mechanism of Regulation of Bcl-2 MRNA by Nucleolin and A+U-rich Element-binding Factor 1 (AUF1)
Overview
Authors
Affiliations
The antiapoptotic Bcl-2 protein is overexpressed in a variety of cancers, particularly leukemias. In some cell types this is the result of enhanced stability of bcl-2 mRNA, which is controlled by elements in its 3'-untranslated region. Nucleolin is one of the proteins that binds to bcl-2 mRNA, thereby increasing its half-life. Here, we examined the site on the bcl-2 3'-untranslated region that is bound by nucleolin as well as the protein binding domains important for bcl-2 mRNA recognition. RNase footprinting and RNA fragment binding assays demonstrated that nucleolin binds to a 40-nucleotide region at the 5' end of the 136-nucleotide bcl-2 AU-rich element (ARE(bcl-2)). The first two RNA binding domains of nucleolin were sufficient for high affinity binding to ARE(bcl-2). In RNA decay assays, ARE(bcl-2) transcripts were protected from exosomal decay by the addition of nucleolin. AUF1 has been shown to recruit the exosome to mRNAs. When MV-4-11 cell extracts were immunodepleted of AUF1, the rate of decay of ARE(bcl-2) transcripts was reduced, indicating that nucleolin and AUF1 have opposing roles in bcl-2 mRNA turnover. When the function of nucleolin in MV-4-11 cells was impaired by treatment with the nucleolin-targeting aptamer AS1411, association of AUF1 with bcl-2 mRNA was increased. This suggests that the degradation of bcl-2 mRNA induced by AS1411 results from both interference with nucleolin protection of bcl-2 mRNA and recruitment of the exosome by AUF1. Based on our findings, we propose a model that illustrates the opposing roles of nucleolin and AUF1 in regulating bcl-2 mRNA stability.
Saidi D, Obeidat M, Alsotari S, Ibrahim A, Al-Buqain R, Wehaibi S Heliyon. 2024; 10(10):e30743.
PMID: 38774322 PMC: 11107208. DOI: 10.1016/j.heliyon.2024.e30743.
Small molecule inhibition of RNA binding proteins in haematologic cancer.
Jaiswal A, Thaxton M, Scherer G, Sorrentino J, Garg N, Rao D RNA Biol. 2024; 21(1):1-14.
PMID: 38329136 PMC: 10857685. DOI: 10.1080/15476286.2024.2303558.
Suchanski J, Reza S, Urbaniak A, Woldanska W, Kocbach B, Ugorski M Cancers (Basel). 2024; 16(2).
PMID: 38254878 PMC: 10813928. DOI: 10.3390/cancers16020389.
Chen S, Zhou Y, Peng P, Xu L, Tang Q, Chen W Int J Mol Sci. 2023; 24(21).
PMID: 37958584 PMC: 10650932. DOI: 10.3390/ijms242115600.
Anti-nucleolin aptamer AS1411: an advancing therapeutic.
Van den Avont A, Sharma-Walia N Front Mol Biosci. 2023; 10:1217769.
PMID: 37808518 PMC: 10551449. DOI: 10.3389/fmolb.2023.1217769.